You are here

Article Text

Article menu
Download PDFPDF
Chronic and interventional pain: Original article
Anatomical Look Into OnabotulinumtoxinA Injection for Chronic Migraine Headache
  1. Yuewei Wu-Fienberg, MD*,
  2. Hossein Ansari, MD†,
  3. Shawn Zardouz, MD†,
  4. Samer Narouze, MD, PhD‡,
  5. Taryn Blaha, BA§,
  6. Marco Swanson, BA∥ and
  7. Ali Totonchi, MD
  1. *From the Department of Plastic Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH;
  2. †Department of Neurology, University of California, San Diego, San Diego, CA; and
  3. ‡Center for Pain Medicine, Western Reserve Hospital, Cuyahoga Falls;
  4. §School of Medicine, Northeast Ohio Medical University, Rootstown; and
  5. ∥School of Medicine and
  6. Department of Surgery, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH
  1. Address correspondence to: Ali Totonchi, MD, Department of Surgery, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 44106 (e-mail: totonchia{at}yahoo.com).

Abstract

Background and Objectives While existing studies about onabotulinumtoxinA for chronic migraines have focused on injection location and appropriate dosing, little consideration has been given to patient body habitus and its potential impact on efficacy. We hypothesized that with increasing patient body mass index (BMI) there would be more subcutaneous fat separating targeted muscle groups from the skin surface, such that standard 0.5-inch needles used in existing protocols may not allow intramuscular injection. This may have implications for treatment planning.

Methods Anatomically normal computed tomography scans of the head, neck, and face were randomly selected. Subjects were stratified into 4 groups based on BMI, with 30 patients in each group. Four standardized locations were chosen to obtain measurements from the skin surface to the underlying muscle fascia, including (1) frontalis, (2) temporalis, (3) semispinalis capitis, and (4) trapezius.

Results Median depth for the temporalis was 12.65 mm (Q1 = 9.32 mm, Q3 = 15.08 mm) for the BMI greater than 35 kg/m2 group. Median depth for the semispinalis capitis was 13.77 mm (Q1 = 10.3 mm, Q3 = 15.7 mm) for the BMI 30 to 35 kg/m2 group, and 14.75 mm (Q1 = 11.00, Q3 = 17.00 mm) for the BMI greater than 35 kg/m2 group. Median depth for the trapezius was 13.95 mm (Q1 = 10.18 mm, Q3 = 19.00 mm) for the BMI greater than 35 kg/m2 group. These medians exceeded the length of the standard 0.5-inch (12.-mm) needle used in existing protocols.

Conclusions Our study demonstrates that with increasing BMI there is a greater distance between the skin surface and the muscle fascia of muscles that are targeted for injection in standard chronic migraine botulinum toxin injection protocols. Because of this, patient body habitus may be an important factor in injection technique.

https://doi.org/10.1097/AAP.0000000000000818

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflict of interest.

    • Interim data from this work were presented at the 2017 Annual Meeting of the Ohio Valley Society of Plastic Surgeons in Pittsburgh, PA, on May 2 to 4, 2017.